Chemicals
Showing 34651–34800 of 41137 results
-
Rosuvastatin is a potent HMG-CoA reductase inhibitor (IC50 = 5 nM).{15309,15082} It is a fully-synthetic inhibitor that is designed to maximize the points of contact with, and inhibition of, HMG-CoA reductase.{15309} Formulations containing rosuvastatin reduce low-density lipoprotein (LDL) and C-reactive protein and increase high-density lipoprotein (HDL) in humans.{16178,30471}
Brand:CaymanSKU:12029 - 5 mgAvailable on backorder
Rosuvastatin is a potent HMG-CoA reductase inhibitor (IC50 = 5 nM).{15309,15082} It is a fully-synthetic inhibitor that is designed to maximize the points of contact with, and inhibition of, HMG-CoA reductase.{15309} Formulations containing rosuvastatin reduce low-density lipoprotein (LDL) and C-reactive protein and increase high-density lipoprotein (HDL) in humans.{16178,30471}
Brand:CaymanSKU:12029 - 50 mgAvailable on backorder
Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase is the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the “statin” class of cholesterol-lowering drugs.{15082} Rosuvastatin is a potent HMG-CoA reductase inhibitor (IC50 = 5 nM).{15309,15082} It is a fully-synthetic inhibitor that is designed to maximize the points of contact with, and inhibition of, HMG-CoA reductase.{15309} Formulations containing rosuvastatin reduce low-density lipoprotein (LDL) and C-reactive protein and increase high-density lipoprotein (HDL) in humans.{16178,30471}
Brand:CaymanSKU:-Available on backorder
Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase is the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the “statin” class of cholesterol-lowering drugs.{15082} Rosuvastatin is a potent HMG-CoA reductase inhibitor (IC50 = 5 nM).{15309,15082} It is a fully-synthetic inhibitor that is designed to maximize the points of contact with, and inhibition of, HMG-CoA reductase.{15309} Formulations containing rosuvastatin reduce low-density lipoprotein (LDL) and C-reactive protein and increase high-density lipoprotein (HDL) in humans.{16178,30471}
Brand:CaymanSKU:-Available on backorder
Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase is the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the “statin” class of cholesterol-lowering drugs.{15082} Rosuvastatin is a potent HMG-CoA reductase inhibitor (IC50 = 5 nM).{15309,15082} It is a fully-synthetic inhibitor that is designed to maximize the points of contact with, and inhibition of, HMG-CoA reductase.{15309} Formulations containing rosuvastatin reduce low-density lipoprotein (LDL) and C-reactive protein and increase high-density lipoprotein (HDL) in humans.{16178,30471}
Brand:CaymanSKU:-Available on backorder
Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase is the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the “statin” class of cholesterol-lowering drugs.{15082} Rosuvastatin is a potent HMG-CoA reductase inhibitor (IC50 = 5 nM).{15309,15082} It is a fully-synthetic inhibitor that is designed to maximize the points of contact with, and inhibition of, HMG-CoA reductase.{15309} Formulations containing rosuvastatin reduce low-density lipoprotein (LDL) and C-reactive protein and increase high-density lipoprotein (HDL) in humans.{16178,30471}
Brand:CaymanSKU:-Available on backorder
Rosuvastatin-d6 is intended for use as an internal standard for the quantification of rosuvastatin (Item Nos. 12029 | 18813) by GC- or LC-MS. Rosuvastatin is an HMG-CoA reductase inhibitor (IC50 = 5 nM).{15309,15082} It is a fully-synthetic inhibitor that is designed to maximize the points of contact with, and inhibition of, HMG-CoA reductase.{15309} Formulations containing rosuvastatin reduce low-density lipoprotein and C-reactive protein and increase high-density lipoprotein in humans.{16178,30471}
Brand:CaymanSKU:23359 - 1 mgAvailable on backorder
Rosuvastatin-d6 is intended for use as an internal standard for the quantification of rosuvastatin (Item Nos. 12029 | 18813) by GC- or LC-MS. Rosuvastatin is an HMG-CoA reductase inhibitor (IC50 = 5 nM).{15309,15082} It is a fully-synthetic inhibitor that is designed to maximize the points of contact with, and inhibition of, HMG-CoA reductase.{15309} Formulations containing rosuvastatin reduce low-density lipoprotein and C-reactive protein and increase high-density lipoprotein in humans.{16178,30471}
Brand:CaymanSKU:23359 - 5 mgAvailable on backorder
Rosuvastatin-d6 is intended for use as an internal standard for the quantification of rosuvastatin (Item Nos. 12029 | 18813) by GC- or LC-MS. Rosuvastatin is an HMG-CoA reductase inhibitor (IC50 = 5 nM).{15309,15082} It is a fully-synthetic inhibitor that is designed to maximize the points of contact with, and inhibition of, HMG-CoA reductase.{15309} Formulations containing rosuvastatin reduce low-density lipoprotein and C-reactive protein and increase high-density lipoprotein in humans.{16178,30471}
Brand:CaymanSKU:23359 - 500 µgAvailable on backorder
Rotenone is a classical inhibitor of complex I of the mitochondrial electron transport chain, inhibiting NADH/DB oxidoreductase and NADH oxidase with IC50 values of 28.8 and 5.1 nM, respectively.{25505} In substantia nigra pars compacta neurons, it activates ATP-sensitive potassium channels and increases the production of reactive oxygen species (ROS) in the mitochondria, effects that are decreased by the antioxidant trolox (Item No. 10011659).{25508} In rodents, rotenone induces dopaminergic cell death in the substantia nigra, formation of cytoplasmic inclusions similar to Lewy bodies, oxidative damage to proteins, and parkinsonian symptoms of bradykinesia and rigidity.{25506} In a rat model of Parkinson’s disease, chronic rotenone administration of 1.5 and 2.5 mg/kg per day for two months reduces tyrosine hydroxylase levels in the posterior striatum and prefrontal cortex, induces catalepsy, and decreases spontaneous locomotion and exploration in the open field test.{41910} Formulations containing rotenone have been used as insecticides and piscicides.{25504}
Brand:CaymanSKU:- Rotenone is a classical inhibitor of complex I of the mitochondrial electron transport chain, inhibiting NADH/DB oxidoreductase and NADH oxidase with IC50 values of 28.8 and 5.1 nM, respectively.{25505} In substantia nigra pars compacta neurons, it activates ATP-sensitive potassium channels and increases the production of reactive oxygen species (ROS) in the mitochondria, effects that are decreased by the antioxidant trolox (Item No. 10011659).{25508} In rodents, rotenone induces dopaminergic cell death in the substantia nigra, formation of cytoplasmic inclusions similar to Lewy bodies, oxidative damage to proteins, and parkinsonian symptoms of bradykinesia and rigidity.{25506} In a rat model of Parkinson’s disease, chronic rotenone administration of 1.5 and 2.5 mg/kg per day for two months reduces tyrosine hydroxylase levels in the posterior striatum and prefrontal cortex, induces catalepsy, and decreases spontaneous locomotion and exploration in the open field test.{41910} Formulations containing rotenone have been used as insecticides and piscicides.{25504}
Brand:CaymanSKU:- Rotenone is a classical inhibitor of complex I of the mitochondrial electron transport chain, inhibiting NADH/DB oxidoreductase and NADH oxidase with IC50 values of 28.8 and 5.1 nM, respectively.{25505} In substantia nigra pars compacta neurons, it activates ATP-sensitive potassium channels and increases the production of reactive oxygen species (ROS) in the mitochondria, effects that are decreased by the antioxidant trolox (Item No. 10011659).{25508} In rodents, rotenone induces dopaminergic cell death in the substantia nigra, formation of cytoplasmic inclusions similar to Lewy bodies, oxidative damage to proteins, and parkinsonian symptoms of bradykinesia and rigidity.{25506} In a rat model of Parkinson’s disease, chronic rotenone administration of 1.5 and 2.5 mg/kg per day for two months reduces tyrosine hydroxylase levels in the posterior striatum and prefrontal cortex, induces catalepsy, and decreases spontaneous locomotion and exploration in the open field test.{41910} Formulations containing rotenone have been used as insecticides and piscicides.{25504}
Brand:CaymanSKU:-
Rotigotine is a non-selective dopamine receptor agonist with pEC50 values of 9.6, 10.4, 8.2, 7.7, and 7.7 for D1, D2, D3, D4, and D5, respectively.{32322} It demonstrates a high-affinity for D1, D2, and D3 with lesser affinity for D4 and D5 receptor subtypes.{32322} This binding profile is similar to that of apomorphine (Item No. 16094) and pergolide but differentiated from that of pramipexole (Item No. 11981) and ropinirole, which have a more narrow profile of receptor specificity.{32322} Each of these agonists demonstrates anti-Parkinsonian effects in animal and clinical models through their ability to directly activate dopamine receptors.{32322}
Brand:CaymanSKU:20246 -Available on backorder
Rotigotine is a non-selective dopamine receptor agonist with pEC50 values of 9.6, 10.4, 8.2, 7.7, and 7.7 for D1, D2, D3, D4, and D5, respectively.{32322} It demonstrates a high-affinity for D1, D2, and D3 with lesser affinity for D4 and D5 receptor subtypes.{32322} This binding profile is similar to that of apomorphine (Item No. 16094) and pergolide but differentiated from that of pramipexole (Item No. 11981) and ropinirole, which have a more narrow profile of receptor specificity.{32322} Each of these agonists demonstrates anti-Parkinsonian effects in animal and clinical models through their ability to directly activate dopamine receptors.{32322}
Brand:CaymanSKU:20246 -Available on backorder
Rotigotine is a non-selective dopamine receptor agonist with pEC50 values of 9.6, 10.4, 8.2, 7.7, and 7.7 for D1, D2, D3, D4, and D5, respectively.{32322} It demonstrates a high-affinity for D1, D2, and D3 with lesser affinity for D4 and D5 receptor subtypes.{32322} This binding profile is similar to that of apomorphine (Item No. 16094) and pergolide but differentiated from that of pramipexole (Item No. 11981) and ropinirole, which have a more narrow profile of receptor specificity.{32322} Each of these agonists demonstrates anti-Parkinsonian effects in animal and clinical models through their ability to directly activate dopamine receptors.{32322}
Brand:CaymanSKU:20246 -Available on backorder
Rotigotine is a non-selective dopamine receptor agonist with pEC50 values of 9.6, 10.4, 8.2, 7.7, and 7.7 for D1, D2, D3, D4, and D5, respectively.{32322} It demonstrates a high-affinity for D1, D2, and D3 with lesser affinity for D4 and D5 receptor subtypes.{32322} This binding profile is similar to that of apomorphine (Item No. 16094) and pergolide but differentiated from that of pramipexole (Item No. 11981) and ropinirole, which have a more narrow profile of receptor specificity.{32322} Each of these agonists demonstrates anti-Parkinsonian effects in animal and clinical models through their ability to directly activate dopamine receptors.{32322}
Brand:CaymanSKU:20246 -Available on backorder
Rottlerin was originally identified as an inhibitor of PKCδ (IC50 = 3 μM), but can also inhibit CAM kinase III and a wide range of protein kinases, including PRAK and MAPKAP-K2 (IC50s = 1.9 and 5 μM, respectively).{22472,12847} It can act as a direct mitochondrial uncoupler, and stimulates autophagy by targeting a signaling cascade upstream of mTORC1.{17472} Rottlerin has also been shown to have neuroprotective effects in an MPTP animal model of Parkinson’s disease.{23036}
Brand:CaymanSKU:12006 - 10 mgAvailable on backorder
Rottlerin was originally identified as an inhibitor of PKCδ (IC50 = 3 μM), but can also inhibit CAM kinase III and a wide range of protein kinases, including PRAK and MAPKAP-K2 (IC50s = 1.9 and 5 μM, respectively).{22472,12847} It can act as a direct mitochondrial uncoupler, and stimulates autophagy by targeting a signaling cascade upstream of mTORC1.{17472} Rottlerin has also been shown to have neuroprotective effects in an MPTP animal model of Parkinson’s disease.{23036}
Brand:CaymanSKU:12006 - 50 mgAvailable on backorder
Roxatidine acetate is a competitive histamine H2 receptor antagonist that upon oral absorption is rapidly converted to its active metabolite roxatidine.{33405} By inhibiting the binding of histamine to H2 receptors, roxatidine reduces both intracellular cAMP concentrations and gastric acid secretion by parietal cells.{33405}
Brand:CaymanSKU:21248 -Out of stock
Roxatidine acetate is a competitive histamine H2 receptor antagonist that upon oral absorption is rapidly converted to its active metabolite roxatidine.{33405} By inhibiting the binding of histamine to H2 receptors, roxatidine reduces both intracellular cAMP concentrations and gastric acid secretion by parietal cells.{33405}
Brand:CaymanSKU:21248 -Out of stock
Roxatidine acetate is a competitive histamine H2 receptor antagonist that upon oral absorption is rapidly converted to its active metabolite roxatidine.{33405} By inhibiting the binding of histamine to H2 receptors, roxatidine reduces both intracellular cAMP concentrations and gastric acid secretion by parietal cells.{33405}
Brand:CaymanSKU:21248 -Out of stock
Roxatidine acetate is a competitive histamine H2 receptor antagonist that upon oral absorption is rapidly converted to its active metabolite roxatidine.{33405} By inhibiting the binding of histamine to H2 receptors, roxatidine reduces both intracellular cAMP concentrations and gastric acid secretion by parietal cells.{33405}
Brand:CaymanSKU:21248 -Out of stock
Roxithromycin is a semi-synthetic macrolide antibiotic in which the erythronolide A lactone ring has been altered to prevent inactivation in the gastric milieu.{31054,22680} It is active against Gram-positive and Gram-negative cocci, Gram-positive bacilli, and some Gram-negative bacilli without significantly affecting the fecal flora.{31054} Roxithromycin is also effective in eradicating H. pylori.{18258}
Brand:CaymanSKU:-Available on backorder
Roxithromycin is a semi-synthetic macrolide antibiotic in which the erythronolide A lactone ring has been altered to prevent inactivation in the gastric milieu.{31054,22680} It is active against Gram-positive and Gram-negative cocci, Gram-positive bacilli, and some Gram-negative bacilli without significantly affecting the fecal flora.{31054} Roxithromycin is also effective in eradicating H. pylori.{18258}
Brand:CaymanSKU:-Available on backorder
Roxithromycin is a semi-synthetic macrolide antibiotic in which the erythronolide A lactone ring has been altered to prevent inactivation in the gastric milieu.{31054,22680} It is active against Gram-positive and Gram-negative cocci, Gram-positive bacilli, and some Gram-negative bacilli without significantly affecting the fecal flora.{31054} Roxithromycin is also effective in eradicating H. pylori.{18258}
Brand:CaymanSKU:-Available on backorder
RP 001 is a potent sphingosine-1-phosphate receptor 1 (S1P1) agonist (EC50 = 9 pM).{27096} It is competitive with W146 (Item No. 10009109), a selective S1P1 antagonist, and induces internalization and polyubiquitination of S1P1 in a dose-dependent manner. RP 001 induces dose-dependent lymphopenia in mice (EC50 = 0.03 mg/kg). It reduces S1P1-EGFP expression ex vivo on lymphocytes in the isolated lymph node of Edg1eGFP/eGFP mice but has no effect in vivo. RP 001 also completely inhibits M. stadtmanae (MSS) rechallenge-induced enlargement of B cell-rich tertiary lymphoid tissues (TLTs) and reduces neutrophil accumulation in the airways of a mouse model of experimental hypersensitivity pneumonitis.{40737}
Brand:CaymanSKU:-Out of stock
RP 001 is a potent sphingosine-1-phosphate receptor 1 (S1P1) agonist (EC50 = 9 pM).{27096} It is competitive with W146 (Item No. 10009109), a selective S1P1 antagonist, and induces internalization and polyubiquitination of S1P1 in a dose-dependent manner. RP 001 induces dose-dependent lymphopenia in mice (EC50 = 0.03 mg/kg). It reduces S1P1-EGFP expression ex vivo on lymphocytes in the isolated lymph node of Edg1eGFP/eGFP mice but has no effect in vivo. RP 001 also completely inhibits M. stadtmanae (MSS) rechallenge-induced enlargement of B cell-rich tertiary lymphoid tissues (TLTs) and reduces neutrophil accumulation in the airways of a mouse model of experimental hypersensitivity pneumonitis.{40737}
Brand:CaymanSKU:-Out of stock
RP 001 is a potent sphingosine-1-phosphate receptor 1 (S1P1) agonist (EC50 = 9 pM).{27096} It is competitive with W146 (Item No. 10009109), a selective S1P1 antagonist, and induces internalization and polyubiquitination of S1P1 in a dose-dependent manner. RP 001 induces dose-dependent lymphopenia in mice (EC50 = 0.03 mg/kg). It reduces S1P1-EGFP expression ex vivo on lymphocytes in the isolated lymph node of Edg1eGFP/eGFP mice but has no effect in vivo. RP 001 also completely inhibits M. stadtmanae (MSS) rechallenge-induced enlargement of B cell-rich tertiary lymphoid tissues (TLTs) and reduces neutrophil accumulation in the airways of a mouse model of experimental hypersensitivity pneumonitis.{40737}
Brand:CaymanSKU:-Out of stock
RP 001 is a potent sphingosine-1-phosphate receptor 1 (S1P1) agonist (EC50 = 9 pM).{27096} It is competitive with W146 (Item No. 10009109), a selective S1P1 antagonist, and induces internalization and polyubiquitination of S1P1 in a dose-dependent manner. RP 001 induces dose-dependent lymphopenia in mice (EC50 = 0.03 mg/kg). It reduces S1P1-EGFP expression ex vivo on lymphocytes in the isolated lymph node of Edg1eGFP/eGFP mice but has no effect in vivo. RP 001 also completely inhibits M. stadtmanae (MSS) rechallenge-induced enlargement of B cell-rich tertiary lymphoid tissues (TLTs) and reduces neutrophil accumulation in the airways of a mouse model of experimental hypersensitivity pneumonitis.{40737}
Brand:CaymanSKU:-Out of stock
Rp-8-bromo-Cyclic AMPS (Rp-8-bromo-cAMPS) is a cell-permeable cAMP analog that combines an exocyclic sulfur substitution in the equatorial position of the cyclophosphate ring with a bromine substitution in the adenine base of cAMP.{26215,28143} It acts as an antagonist of cAMP-dependent protein kinases (PKAs) and is resistant to hydrolysis by cyclic nucleotide phosphodiesterases. Rp-8-bromo-cAMPS more effectively antagonizes cAMP-dependent activation of purified PKA type I from rabbit muscle than PKA type II from bovine heart.{28143}
Brand:CaymanSKU:21584 -Out of stock
Rp-8-bromo-Cyclic AMPS (Rp-8-bromo-cAMPS) is a cell-permeable cAMP analog that combines an exocyclic sulfur substitution in the equatorial position of the cyclophosphate ring with a bromine substitution in the adenine base of cAMP.{26215,28143} It acts as an antagonist of cAMP-dependent protein kinases (PKAs) and is resistant to hydrolysis by cyclic nucleotide phosphodiesterases. Rp-8-bromo-cAMPS more effectively antagonizes cAMP-dependent activation of purified PKA type I from rabbit muscle than PKA type II from bovine heart.{28143}
Brand:CaymanSKU:21584 -Out of stock
Rp-8-bromo-Cyclic AMPS (Rp-8-bromo-cAMPS) is a cell-permeable cAMP analog that combines an exocyclic sulfur substitution in the equatorial position of the cyclophosphate ring with a bromine substitution in the adenine base of cAMP.{26215,28143} It acts as an antagonist of cAMP-dependent protein kinases (PKAs) and is resistant to hydrolysis by cyclic nucleotide phosphodiesterases. Rp-8-bromo-cAMPS more effectively antagonizes cAMP-dependent activation of purified PKA type I from rabbit muscle than PKA type II from bovine heart.{28143}
Brand:CaymanSKU:21584 -Out of stock
8-bromo-cGMP (Item No. 15992) is a cell-permeable analog of cGMP that exhibits resistance to hydrolysis by phosphodiesterases. It preferentially activates cGMP-dependent protein kinase (cGK).{25938} Rp-8-bromo-Cyclic GMPS (Rp-8-bromo-cGMPS) is a cell-permeable cGMP analog that adds an equatorial exocyclic (Rp) sulfur substitution in the axial position of the cyclophosphate ring of 8-bromo-cGMP. Like 8-bromo-cGMP, Rp-8-bromo-cGMPS is resistant to hydrolysis by phosphodiesterases. This Rp isomer binds cGK without activating it, resulting in competitive inhibition.{29700,29701} At 10 µM, it blocks the relaxation of rat tail arteries induced by the nitric oxide donor SIN-1 (Item No. 82220).{29702}
Brand:CaymanSKU:-Available on backorder
8-bromo-cGMP (Item No. 15992) is a cell-permeable analog of cGMP that exhibits resistance to hydrolysis by phosphodiesterases. It preferentially activates cGMP-dependent protein kinase (cGK).{25938} Rp-8-bromo-Cyclic GMPS (Rp-8-bromo-cGMPS) is a cell-permeable cGMP analog that adds an equatorial exocyclic (Rp) sulfur substitution in the axial position of the cyclophosphate ring of 8-bromo-cGMP. Like 8-bromo-cGMP, Rp-8-bromo-cGMPS is resistant to hydrolysis by phosphodiesterases. This Rp isomer binds cGK without activating it, resulting in competitive inhibition.{29700,29701} At 10 µM, it blocks the relaxation of rat tail arteries induced by the nitric oxide donor SIN-1 (Item No. 82220).{29702}
Brand:CaymanSKU:-Available on backorder
Rp-8-bromo-PET-Cyclic GMPS (Rp-8-bromo-PET-cGMPS) is an analog of cyclic GMP (cGMP). It is a cell permeable, competitive, and reversible inhibitor of cGMP-dependent protein kinases (cGKs) that blocks activation of cGKI and cGKII by cGMP (Kis = 35 and 30 nM).{29701,30362} It less potently inhibits protein kinase A (Ki = 11 µM) and cGMP-induced activation of cyclic nucleotide-gated channels (IC50 = 25 µM).{29701,30363} In the absence of cGMP stimulation, Rp-8-bromo-PET-cGMPS can act as a partial agonist of cGKI (Ki = 1 µM).{30362} Rp-8-bromo-PET-cGMPS is resistant to hydrolysis by phosphodiesterase 11.{24263}
Brand:CaymanSKU:-Available on backorder
Rp-8-bromo-PET-Cyclic GMPS (Rp-8-bromo-PET-cGMPS) is an analog of cyclic GMP (cGMP). It is a cell permeable, competitive, and reversible inhibitor of cGMP-dependent protein kinases (cGKs) that blocks activation of cGKI and cGKII by cGMP (Kis = 35 and 30 nM).{29701,30362} It less potently inhibits protein kinase A (Ki = 11 µM) and cGMP-induced activation of cyclic nucleotide-gated channels (IC50 = 25 µM).{29701,30363} In the absence of cGMP stimulation, Rp-8-bromo-PET-cGMPS can act as a partial agonist of cGKI (Ki = 1 µM).{30362} Rp-8-bromo-PET-cGMPS is resistant to hydrolysis by phosphodiesterase 11.{24263}
Brand:CaymanSKU:-Available on backorder
Rp-8-CPT-cAMP is a structural combination of the lipophilic and non-hydrolyzable cAMP analogs, 8-CPT-cyclic AMP (Item No. 12011) and Rp-cyclic AMPS (Item No. 16985).{26217} It functions as a site-selective inhibitor of protein kinase A (PKA) type I and II, with preference towards site A of type I and site B of type II.{26215} By occupying cAMP binding sites at the regulatory subunit of PKA, Rp-8-CPT-cAMP prevents the kinase holoenzyme from dissociative activation.{26215,28143}
Brand:CaymanSKU:-Out of stock
Rp-8-CPT-cAMP is a structural combination of the lipophilic and non-hydrolyzable cAMP analogs, 8-CPT-cyclic AMP (Item No. 12011) and Rp-cyclic AMPS (Item No. 16985).{26217} It functions as a site-selective inhibitor of protein kinase A (PKA) type I and II, with preference towards site A of type I and site B of type II.{26215} By occupying cAMP binding sites at the regulatory subunit of PKA, Rp-8-CPT-cAMP prevents the kinase holoenzyme from dissociative activation.{26215,28143}
Brand:CaymanSKU:-Out of stock
Rp-8-pCPT-Cyclic GMPS is a stable, cell-permeable cGMP analog that competitively inhibits cGMP-dependent protein kinases (cGKs), including cGK Iα and cGK II (IC50s = 18.3 and 0.16 µM, respectively).{29685} The pCPT (p-chlorophenylthio) group at the 8-position of the purine increases both enzyme affinity and membrane permeability over related compounds.{29686} At 10 µM, it blocks the relaxation of rat tail arteries induced by the nitric oxide donor SIN-1 (Item No. 82220).{29702}
Brand:CaymanSKU:-Available on backorder
Rp-Cyclic AMPS (Rp-cAMPS) is a non-hydrolyzable phosphorothioate analog of cAMP.{26216} It is a competitive inhibitor of cAMP-dependent protein kinases I and II (IC50s = 12.5 and 4.5 µM, respectively).{27707,27705} Rp-cAMPS is not hydrolyzed by bovine heart cAMP phosphodiesterase but can be hydrolyzed by yeast phosphodiesterase.{27706} It is broadly used in research involving cAMP-dependent signaling in vitro and in vivo.{26216,26217,26218}
Brand:CaymanSKU:-Out of stock
Rp-Cyclic AMPS (Rp-cAMPS) is a non-hydrolyzable phosphorothioate analog of cAMP.{26216} It is a competitive inhibitor of cAMP-dependent protein kinases I and II (IC50s = 12.5 and 4.5 µM, respectively).{27707,27705} Rp-cAMPS is not hydrolyzed by bovine heart cAMP phosphodiesterase but can be hydrolyzed by yeast phosphodiesterase.{27706} It is broadly used in research involving cAMP-dependent signaling in vitro and in vivo.{26216,26217,26218}
Brand:CaymanSKU:-Out of stock
Rp-Cyclic AMPS (Rp-cAMPS) is a non-hydrolyzable phosphorothioate analog of cAMP.{26216} It is a competitive inhibitor of cAMP-dependent protein kinases I and II (IC50s = 12.5 and 4.5 µM, respectively).{27707,27705} Rp-cAMPS is not hydrolyzed by bovine heart cAMP phosphodiesterase but can be hydrolyzed by yeast phosphodiesterase.{27706} It is broadly used in research involving cAMP-dependent signaling in vitro and in vivo.{26216,26217,26218}
Brand:CaymanSKU:-Out of stock
RPI-1 is an ATP-dependent RET kinase inhibitor. It has been shown to selectively inhibit the anchorage-independent growth of NIH3T3 cells transformed by the ret/ptc1 oncogene with an IC50 value of 0.97 µM.{32109} In a spontaneously metastasizing lung carcinoma xenograft mouse model, daily oral treatment with RPI-1 was reported to significantly reduce spontaneous lung metastases.{32108}
Brand:CaymanSKU:20384 -Available on backorder
RPI-1 is an ATP-dependent RET kinase inhibitor. It has been shown to selectively inhibit the anchorage-independent growth of NIH3T3 cells transformed by the ret/ptc1 oncogene with an IC50 value of 0.97 µM.{32109} In a spontaneously metastasizing lung carcinoma xenograft mouse model, daily oral treatment with RPI-1 was reported to significantly reduce spontaneous lung metastases.{32108}
Brand:CaymanSKU:20384 -Available on backorder
RPI-1 is an ATP-dependent RET kinase inhibitor. It has been shown to selectively inhibit the anchorage-independent growth of NIH3T3 cells transformed by the ret/ptc1 oncogene with an IC50 value of 0.97 µM.{32109} In a spontaneously metastasizing lung carcinoma xenograft mouse model, daily oral treatment with RPI-1 was reported to significantly reduce spontaneous lung metastases.{32108}
Brand:CaymanSKU:20384 -Available on backorder
RPI-1 is an ATP-dependent RET kinase inhibitor. It has been shown to selectively inhibit the anchorage-independent growth of NIH3T3 cells transformed by the ret/ptc1 oncogene with an IC50 value of 0.97 µM.{32109} In a spontaneously metastasizing lung carcinoma xenograft mouse model, daily oral treatment with RPI-1 was reported to significantly reduce spontaneous lung metastases.{32108}
Brand:CaymanSKU:20384 -Available on backorder
RQ-00203078 is a selective antagonist of transient receptor potential melastatin 8 (TRPM8; IC50s = 8.3 and 5.8 nM in human and rat, respectively), while having little inhibitory action against TRPV1 (IC50 > 30 µM), TRPA1 (IC50 > 10 µM), TRPV4 (IC50 = 10 µM), or TRPM2 channels (IC50 > 10 µM).{31190} It attenuates icilin-induced wet-dog shakes in rats (ED50 = 0.65 mg/kg) after oral administration.{31190} RQ-00203078 has been shown to reduce HSC3 and HSC4 oral squamous carcinoma cell migration and invasion in vitro.{31191} TRPM8, a member of the TRP melastatin subgroup, plays a role in cold hyperalgesia and cold allodynia caused by disease conditions such as chemotherapy-induced peripheral neuropathy, diabetic neuropathy, migraine, and overactive bladder. It is also known to be involved in the tumor progression of certain carcinomas.
Brand:CaymanSKU:-Available on backorder
RQ-00203078 is a selective antagonist of transient receptor potential melastatin 8 (TRPM8; IC50s = 8.3 and 5.8 nM in human and rat, respectively), while having little inhibitory action against TRPV1 (IC50 > 30 µM), TRPA1 (IC50 > 10 µM), TRPV4 (IC50 = 10 µM), or TRPM2 channels (IC50 > 10 µM).{31190} It attenuates icilin-induced wet-dog shakes in rats (ED50 = 0.65 mg/kg) after oral administration.{31190} RQ-00203078 has been shown to reduce HSC3 and HSC4 oral squamous carcinoma cell migration and invasion in vitro.{31191} TRPM8, a member of the TRP melastatin subgroup, plays a role in cold hyperalgesia and cold allodynia caused by disease conditions such as chemotherapy-induced peripheral neuropathy, diabetic neuropathy, migraine, and overactive bladder. It is also known to be involved in the tumor progression of certain carcinomas.
Brand:CaymanSKU:-Available on backorder
RQ-00203078 is a selective antagonist of transient receptor potential melastatin 8 (TRPM8; IC50s = 8.3 and 5.8 nM in human and rat, respectively), while having little inhibitory action against TRPV1 (IC50 > 30 µM), TRPA1 (IC50 > 10 µM), TRPV4 (IC50 = 10 µM), or TRPM2 channels (IC50 > 10 µM).{31190} It attenuates icilin-induced wet-dog shakes in rats (ED50 = 0.65 mg/kg) after oral administration.{31190} RQ-00203078 has been shown to reduce HSC3 and HSC4 oral squamous carcinoma cell migration and invasion in vitro.{31191} TRPM8, a member of the TRP melastatin subgroup, plays a role in cold hyperalgesia and cold allodynia caused by disease conditions such as chemotherapy-induced peripheral neuropathy, diabetic neuropathy, migraine, and overactive bladder. It is also known to be involved in the tumor progression of certain carcinomas.
Brand:CaymanSKU:-Available on backorder
RRx-001 is an anticancer agent.{49432} It inhibits growth in a panel of 12 cancer cell lines (IC50s =1.8-6 μM), an effect that is enhanced in SCC VII cells under hypoxic conditions. RRx-001 increases intracellular levels of reactive oxygen species (ROS) in HT-29 and SCC VII cells in a concentration- and time-dependent manner and induces apoptosis in SCC VII, HL-60, and Daudi cells when used at concentrations of 5, 5, and 4 μM, respectively. RRx-001 (5 mg/kg per day for five days) reduces tumor growth and enhances radiation-induced tumor growth reduction in an SCC VII murine squamous cell carcinoma model. Pre-incubation of red blood cells and hemolysate with RRx-001 (3 mM) increases nitrite-induced nitric oxide (NO) release under hypoxic conditions.{49433} RRx-001 (10 mg/kg) also decreases parasitemia and increases survival in a mouse model of P. berghei ANKA infection.{49434}
Brand:CaymanSKU:28846 - 1 mgAvailable on backorder
RRx-001 is an anticancer agent.{49432} It inhibits growth in a panel of 12 cancer cell lines (IC50s =1.8-6 μM), an effect that is enhanced in SCC VII cells under hypoxic conditions. RRx-001 increases intracellular levels of reactive oxygen species (ROS) in HT-29 and SCC VII cells in a concentration- and time-dependent manner and induces apoptosis in SCC VII, HL-60, and Daudi cells when used at concentrations of 5, 5, and 4 μM, respectively. RRx-001 (5 mg/kg per day for five days) reduces tumor growth and enhances radiation-induced tumor growth reduction in an SCC VII murine squamous cell carcinoma model. Pre-incubation of red blood cells and hemolysate with RRx-001 (3 mM) increases nitrite-induced nitric oxide (NO) release under hypoxic conditions.{49433} RRx-001 (10 mg/kg) also decreases parasitemia and increases survival in a mouse model of P. berghei ANKA infection.{49434}
Brand:CaymanSKU:28846 - 10 mgAvailable on backorder
RRx-001 is an anticancer agent.{49432} It inhibits growth in a panel of 12 cancer cell lines (IC50s =1.8-6 μM), an effect that is enhanced in SCC VII cells under hypoxic conditions. RRx-001 increases intracellular levels of reactive oxygen species (ROS) in HT-29 and SCC VII cells in a concentration- and time-dependent manner and induces apoptosis in SCC VII, HL-60, and Daudi cells when used at concentrations of 5, 5, and 4 μM, respectively. RRx-001 (5 mg/kg per day for five days) reduces tumor growth and enhances radiation-induced tumor growth reduction in an SCC VII murine squamous cell carcinoma model. Pre-incubation of red blood cells and hemolysate with RRx-001 (3 mM) increases nitrite-induced nitric oxide (NO) release under hypoxic conditions.{49433} RRx-001 (10 mg/kg) also decreases parasitemia and increases survival in a mouse model of P. berghei ANKA infection.{49434}
Brand:CaymanSKU:28846 - 25 mgAvailable on backorder
RRx-001 is an anticancer agent.{49432} It inhibits growth in a panel of 12 cancer cell lines (IC50s =1.8-6 μM), an effect that is enhanced in SCC VII cells under hypoxic conditions. RRx-001 increases intracellular levels of reactive oxygen species (ROS) in HT-29 and SCC VII cells in a concentration- and time-dependent manner and induces apoptosis in SCC VII, HL-60, and Daudi cells when used at concentrations of 5, 5, and 4 μM, respectively. RRx-001 (5 mg/kg per day for five days) reduces tumor growth and enhances radiation-induced tumor growth reduction in an SCC VII murine squamous cell carcinoma model. Pre-incubation of red blood cells and hemolysate with RRx-001 (3 mM) increases nitrite-induced nitric oxide (NO) release under hypoxic conditions.{49433} RRx-001 (10 mg/kg) also decreases parasitemia and increases survival in a mouse model of P. berghei ANKA infection.{49434}
Brand:CaymanSKU:28846 - 5 mgAvailable on backorder
RS 102221 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT2C.{53989} It binds to 5-HT2C receptors (Ki = 3.8 nM for the recombinant human receptor) and is selective for 5-HT2C receptors over 5-HT2A and 5-HT2B receptors (Kis = 1,122.02 and 812.83 nM, respectively), as well as a panel of additional neurotransmitter receptors and ion channels (Kis = ≥316.23 nM for all). RS 102221 inhibits 5-HT-induced increases in the extracellular media acidification rate of CHO-K1 cells expressing human 5-HT2C receptors (pA2 = 8.1). It increases food intake and weight gain in rats when administered at a dose of 2 mg/kg. RS 102221 (2 mg/kg) increases the time spent in the light compartment in the light-dark exploration test in mice and reduces prepulse inhibition of the startle reflex when administered at a dose of 1 mg/kg.{53990}
Brand:CaymanSKU:31543 - 1 mgAvailable on backorder
RS 102221 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT2C.{53989} It binds to 5-HT2C receptors (Ki = 3.8 nM for the recombinant human receptor) and is selective for 5-HT2C receptors over 5-HT2A and 5-HT2B receptors (Kis = 1,122.02 and 812.83 nM, respectively), as well as a panel of additional neurotransmitter receptors and ion channels (Kis = ≥316.23 nM for all). RS 102221 inhibits 5-HT-induced increases in the extracellular media acidification rate of CHO-K1 cells expressing human 5-HT2C receptors (pA2 = 8.1). It increases food intake and weight gain in rats when administered at a dose of 2 mg/kg. RS 102221 (2 mg/kg) increases the time spent in the light compartment in the light-dark exploration test in mice and reduces prepulse inhibition of the startle reflex when administered at a dose of 1 mg/kg.{53990}
Brand:CaymanSKU:31543 - 5 mgAvailable on backorder
RS 102221 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT2C.{53989} It binds to 5-HT2C receptors (Ki = 3.8 nM for the recombinant human receptor) and is selective for 5-HT2C receptors over 5-HT2A and 5-HT2B receptors (Kis = 1,122.02 and 812.83 nM, respectively), as well as a panel of additional neurotransmitter receptors and ion channels (Kis = ≥316.23 nM for all). RS 102221 inhibits 5-HT-induced increases in the extracellular media acidification rate of CHO-K1 cells expressing human 5-HT2C receptors (pA2 = 8.1). It increases food intake and weight gain in rats when administered at a dose of 2 mg/kg. RS 102221 (2 mg/kg) increases the time spent in the light compartment in the light-dark exploration test in mice and reduces prepulse inhibition of the startle reflex when administered at a dose of 1 mg/kg.{53990}
Brand:CaymanSKU:31543 - 500 µgAvailable on backorder
The chemokine CCL2, also known as monocyte chemotactic protein-1 (MCP-1), stimulates leukocyte chemotaxis to sites of inflammation via signaling through the MCP-1 receptor, CCR2. RS 102895 is a spiropiperidine compound that acts as a CCR2 antagonist (IC50 = 0.36 µM).{29459} It inhibits the related CCR1 receptor with an IC50 value of 17.8 µM and inhibits adrenergic α1a, α1d, and 5HT1A receptors with IC50 values of 0.13, 0.32, and 47 µM, respectively.{29459} RS 102895 prevents chemotaxis of THP-1 cells (IC50 = 1.7 µM) when MCP-1 is presented as a chemoattractant.{29459}
Brand:CaymanSKU:-Available on backorder
The chemokine CCL2, also known as monocyte chemotactic protein-1 (MCP-1), stimulates leukocyte chemotaxis to sites of inflammation via signaling through the MCP-1 receptor, CCR2. RS 102895 is a spiropiperidine compound that acts as a CCR2 antagonist (IC50 = 0.36 µM).{29459} It inhibits the related CCR1 receptor with an IC50 value of 17.8 µM and inhibits adrenergic α1a, α1d, and 5HT1A receptors with IC50 values of 0.13, 0.32, and 47 µM, respectively.{29459} RS 102895 prevents chemotaxis of THP-1 cells (IC50 = 1.7 µM) when MCP-1 is presented as a chemoattractant.{29459}
Brand:CaymanSKU:-Available on backorder
The chemokine CCL2, also known as monocyte chemotactic protein-1 (MCP-1), stimulates leukocyte chemotaxis to sites of inflammation via signaling through the MCP-1 receptor, CCR2. RS 102895 is a spiropiperidine compound that acts as a CCR2 antagonist (IC50 = 0.36 µM).{29459} It inhibits the related CCR1 receptor with an IC50 value of 17.8 µM and inhibits adrenergic α1a, α1d, and 5HT1A receptors with IC50 values of 0.13, 0.32, and 47 µM, respectively.{29459} RS 102895 prevents chemotaxis of THP-1 cells (IC50 = 1.7 µM) when MCP-1 is presented as a chemoattractant.{29459}
Brand:CaymanSKU:-Available on backorder
The chemokine CCL2, also known as monocyte chemotactic protein-1 (MCP-1), stimulates leukocyte chemotaxis to sites of inflammation via signaling through the MCP-1 receptor, CCR2. RS 102895 is a spiropiperidine compound that acts as a CCR2 antagonist (IC50 = 0.36 µM).{29459} It inhibits the related CCR1 receptor with an IC50 value of 17.8 µM and inhibits adrenergic α1a, α1d, and 5HT1A receptors with IC50 values of 0.13, 0.32, and 47 µM, respectively.{29459} RS 102895 prevents chemotaxis of THP-1 cells (IC50 = 1.7 µM) when MCP-1 is presented as a chemoattractant.{29459}
Brand:CaymanSKU:-Available on backorder
RS 127445 is an orally bioavailable and potent antagonist of the serotonin (5-HT) receptor subtype 5-HT2B (Ki = 0.32 nM).{36203} It is selective for 5-HT2B over other 5-HT receptor subtypes (Ki = >3 μM for 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C, 5-HT3, 5-HT5, and 5-HT6). RS 127445 reduces contraction of rat isolated stomach fundus (pA2 = 9.5) and lowers intracellular increases in calcium (IC50 = 0.04 nM) induced by 5-HT (Item No. 14332). It also blocks (±)-α-methyl-5-HT-induced relaxation of isolated rat jugular veins (pA2 = 9.95). RS 127445 (1-30 mg/kg) reduces peristaltic frequency and fecal output in mice in a dose-dependent manner.{36204} Systemic administration of RS 127445 (0.16 mg/kg) reduces basal, but not cocaine-induced, dopamine outflow in the nucleus accumbens of rats and decreases hyperlocomotion induced by cocaine (Item Nos. ISO60176 | 16186 | 22165) or quinpirole.{36202}
Brand:CaymanSKU:23451 - 1 mgAvailable on backorder
RS 127445 is an orally bioavailable and potent antagonist of the serotonin (5-HT) receptor subtype 5-HT2B (Ki = 0.32 nM).{36203} It is selective for 5-HT2B over other 5-HT receptor subtypes (Ki = >3 μM for 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C, 5-HT3, 5-HT5, and 5-HT6). RS 127445 reduces contraction of rat isolated stomach fundus (pA2 = 9.5) and lowers intracellular increases in calcium (IC50 = 0.04 nM) induced by 5-HT (Item No. 14332). It also blocks (±)-α-methyl-5-HT-induced relaxation of isolated rat jugular veins (pA2 = 9.95). RS 127445 (1-30 mg/kg) reduces peristaltic frequency and fecal output in mice in a dose-dependent manner.{36204} Systemic administration of RS 127445 (0.16 mg/kg) reduces basal, but not cocaine-induced, dopamine outflow in the nucleus accumbens of rats and decreases hyperlocomotion induced by cocaine (Item Nos. ISO60176 | 16186 | 22165) or quinpirole.{36202}
Brand:CaymanSKU:23451 - 10 mgAvailable on backorder
RS 127445 is an orally bioavailable and potent antagonist of the serotonin (5-HT) receptor subtype 5-HT2B (Ki = 0.32 nM).{36203} It is selective for 5-HT2B over other 5-HT receptor subtypes (Ki = >3 μM for 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C, 5-HT3, 5-HT5, and 5-HT6). RS 127445 reduces contraction of rat isolated stomach fundus (pA2 = 9.5) and lowers intracellular increases in calcium (IC50 = 0.04 nM) induced by 5-HT (Item No. 14332). It also blocks (±)-α-methyl-5-HT-induced relaxation of isolated rat jugular veins (pA2 = 9.95). RS 127445 (1-30 mg/kg) reduces peristaltic frequency and fecal output in mice in a dose-dependent manner.{36204} Systemic administration of RS 127445 (0.16 mg/kg) reduces basal, but not cocaine-induced, dopamine outflow in the nucleus accumbens of rats and decreases hyperlocomotion induced by cocaine (Item Nos. ISO60176 | 16186 | 22165) or quinpirole.{36202}
Brand:CaymanSKU:23451 - 5 mgAvailable on backorder
RS 504393 is a selective antagonist of the MCP-1 receptor CCR2 (IC50s = 89 nM and >100 μM for CCR2 and CCR1, respectively).{29459} It has been shown to inhibit MCP-1-stimulated chemotaxis (IC50 = 330 nM) and ischemia-reperfusion injury in kidneys.{29459,32283}
Brand:CaymanSKU:-Available on backorder
RS 504393 is a selective antagonist of the MCP-1 receptor CCR2 (IC50s = 89 nM and >100 μM for CCR2 and CCR1, respectively).{29459} It has been shown to inhibit MCP-1-stimulated chemotaxis (IC50 = 330 nM) and ischemia-reperfusion injury in kidneys.{29459,32283}
Brand:CaymanSKU:-Available on backorder
RS 504393 is a selective antagonist of the MCP-1 receptor CCR2 (IC50s = 89 nM and >100 μM for CCR2 and CCR1, respectively).{29459} It has been shown to inhibit MCP-1-stimulated chemotaxis (IC50 = 330 nM) and ischemia-reperfusion injury in kidneys.{29459,32283}
Brand:CaymanSKU:-Available on backorder
RS 504393 is a selective antagonist of the MCP-1 receptor CCR2 (IC50s = 89 nM and >100 μM for CCR2 and CCR1, respectively).{29459} It has been shown to inhibit MCP-1-stimulated chemotaxis (IC50 = 330 nM) and ischemia-reperfusion injury in kidneys.{29459,32283}
Brand:CaymanSKU:-Available on backorder
RS-1 is an activator of DNA repair protein RAD51 (Kd = 48-107 for human RAD51 with different cofactors present).{32860} It stimulates homologous strand assimilation activity at least 5- to 11-old, enhancing homologous recombination activity of hRAD51.{32860} RS-1 is a potent enhancer of CRISPR-mediated genome editing, increasing homology directed repair 3- to 6-fold.{32862} It is used to increase CRISPR-mediated knock-in efficiencies in vitro and in vivo.{32861,32862,32863}
Brand:CaymanSKU:21037 -Out of stock
RS-1 is an activator of DNA repair protein RAD51 (Kd = 48-107 for human RAD51 with different cofactors present).{32860} It stimulates homologous strand assimilation activity at least 5- to 11-old, enhancing homologous recombination activity of hRAD51.{32860} RS-1 is a potent enhancer of CRISPR-mediated genome editing, increasing homology directed repair 3- to 6-fold.{32862} It is used to increase CRISPR-mediated knock-in efficiencies in vitro and in vivo.{32861,32862,32863}
Brand:CaymanSKU:21037 -Out of stock
RS-1 is an activator of DNA repair protein RAD51 (Kd = 48-107 for human RAD51 with different cofactors present).{32860} It stimulates homologous strand assimilation activity at least 5- to 11-old, enhancing homologous recombination activity of hRAD51.{32860} RS-1 is a potent enhancer of CRISPR-mediated genome editing, increasing homology directed repair 3- to 6-fold.{32862} It is used to increase CRISPR-mediated knock-in efficiencies in vitro and in vivo.{32861,32862,32863}
Brand:CaymanSKU:21037 -Out of stock
RS-1 is an activator of DNA repair protein RAD51 (Kd = 48-107 for human RAD51 with different cofactors present).{32860} It stimulates homologous strand assimilation activity at least 5- to 11-old, enhancing homologous recombination activity of hRAD51.{32860} RS-1 is a potent enhancer of CRISPR-mediated genome editing, increasing homology directed repair 3- to 6-fold.{32862} It is used to increase CRISPR-mediated knock-in efficiencies in vitro and in vivo.{32861,32862,32863}
Brand:CaymanSKU:21037 -Out of stock
RSC-133 is an indole compound that promotes the reprogramming of human somatic cells to pluripotent stem cells.{24835} Specifically, when used at 10 μM with four standard reprogramming factors, it increases the number of human foreskin fibroblasts that express the stem cell marker alkaline phosphatase.{24835} RSC-133 induces pluripotency by both down-regulating inducers of cellular senescence and inhibiting DNA methyltransferase and histone deacetylase activities.{24835}
Brand:CaymanSKU:9001839 - 1 mgAvailable on backorder
RSC-133 is an indole compound that promotes the reprogramming of human somatic cells to pluripotent stem cells.{24835} Specifically, when used at 10 μM with four standard reprogramming factors, it increases the number of human foreskin fibroblasts that express the stem cell marker alkaline phosphatase.{24835} RSC-133 induces pluripotency by both down-regulating inducers of cellular senescence and inhibiting DNA methyltransferase and histone deacetylase activities.{24835}
Brand:CaymanSKU:9001839 - 10 mgAvailable on backorder
RSC-133 is an indole compound that promotes the reprogramming of human somatic cells to pluripotent stem cells.{24835} Specifically, when used at 10 μM with four standard reprogramming factors, it increases the number of human foreskin fibroblasts that express the stem cell marker alkaline phosphatase.{24835} RSC-133 induces pluripotency by both down-regulating inducers of cellular senescence and inhibiting DNA methyltransferase and histone deacetylase activities.{24835}
Brand:CaymanSKU:9001839 - 25 mgAvailable on backorder
RSC-133 is an indole compound that promotes the reprogramming of human somatic cells to pluripotent stem cells.{24835} Specifically, when used at 10 μM with four standard reprogramming factors, it increases the number of human foreskin fibroblasts that express the stem cell marker alkaline phosphatase.{24835} RSC-133 induces pluripotency by both down-regulating inducers of cellular senescence and inhibiting DNA methyltransferase and histone deacetylase activities.{24835}
Brand:CaymanSKU:9001839 - 5 mgAvailable on backorder
RSM-932A is a selective inhibitor of choline kinase α (CHOKα; IC50s = 1 and >50 μM for CHOKα and β, respectively).{38678} It induces apoptosis via CHOP signaling and endoplasmic reticulum (ER) stress in MDA-MB-231, MCF-7, SW620, and H460 cancer cells, but it only induces cell cycle arrest and not apoptosis in NCM460 and MCF-10A normal epithelial cells.{38679} RSM-932A inhibits the growth of HT-29 colon cancer cells in vitro (IC50 = 1.15 μM) and in vivo in a mouse xenograft model (ED50 = 7.5 mg/kg).{38678}
Brand:CaymanSKU:21518 -Out of stock
RSM-932A is a selective inhibitor of choline kinase α (CHOKα; IC50s = 1 and >50 μM for CHOKα and β, respectively).{38678} It induces apoptosis via CHOP signaling and endoplasmic reticulum (ER) stress in MDA-MB-231, MCF-7, SW620, and H460 cancer cells, but it only induces cell cycle arrest and not apoptosis in NCM460 and MCF-10A normal epithelial cells.{38679} RSM-932A inhibits the growth of HT-29 colon cancer cells in vitro (IC50 = 1.15 μM) and in vivo in a mouse xenograft model (ED50 = 7.5 mg/kg).{38678}
Brand:CaymanSKU:21518 -Out of stock
RSM-932A is a selective inhibitor of choline kinase α (CHOKα; IC50s = 1 and >50 μM for CHOKα and β, respectively).{38678} It induces apoptosis via CHOP signaling and endoplasmic reticulum (ER) stress in MDA-MB-231, MCF-7, SW620, and H460 cancer cells, but it only induces cell cycle arrest and not apoptosis in NCM460 and MCF-10A normal epithelial cells.{38679} RSM-932A inhibits the growth of HT-29 colon cancer cells in vitro (IC50 = 1.15 μM) and in vivo in a mouse xenograft model (ED50 = 7.5 mg/kg).{38678}
Brand:CaymanSKU:21518 -Out of stock
RSV-604 is an inhibitor of respiratory syncytial virus (RSV) that binds to RSV nucleoprotein (Kd = 1.31 μM).{47701} It reduces plaque formation by RSS, Long, A2, and B RSV strains (EC50s = 0.9, 0.8, 0.5, and 0.6 μM, respectively) and is active against 40 RSV clinical isolates (mean EC50 = 0.8 μM).{47702} RSV-604 increases viability of RSV-infected HEp-2 cells (EC50 = 0.86 μM) and inhibits RSV replication in human airway epithelial (HAE) cell monolayers following mucosal inoculation.
Brand:CaymanSKU:29041 - 1 mgAvailable on backorder
RSV-604 is an inhibitor of respiratory syncytial virus (RSV) that binds to RSV nucleoprotein (Kd = 1.31 μM).{47701} It reduces plaque formation by RSS, Long, A2, and B RSV strains (EC50s = 0.9, 0.8, 0.5, and 0.6 μM, respectively) and is active against 40 RSV clinical isolates (mean EC50 = 0.8 μM).{47702} RSV-604 increases viability of RSV-infected HEp-2 cells (EC50 = 0.86 μM) and inhibits RSV replication in human airway epithelial (HAE) cell monolayers following mucosal inoculation.
Brand:CaymanSKU:29041 - 10 mgAvailable on backorder
RSV-604 is an inhibitor of respiratory syncytial virus (RSV) that binds to RSV nucleoprotein (Kd = 1.31 μM).{47701} It reduces plaque formation by RSS, Long, A2, and B RSV strains (EC50s = 0.9, 0.8, 0.5, and 0.6 μM, respectively) and is active against 40 RSV clinical isolates (mean EC50 = 0.8 μM).{47702} RSV-604 increases viability of RSV-infected HEp-2 cells (EC50 = 0.86 μM) and inhibits RSV replication in human airway epithelial (HAE) cell monolayers following mucosal inoculation.
Brand:CaymanSKU:29041 - 25 mgAvailable on backorder